


Claims

1. A phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:



5 wherein

R^1 represents alkyl optionally substituted by one or two substituents selected from the group consisting of alkoxy, amino, alkylamino, di(alkyl)amino, alkanoyloxy, hydroxy, carboxy, alkoxycarbonyl, cycloalkylphenyloxy, halogen, morpholino, carbamoyl, alkylsulfonylamino, phenyloxy optionally substituted by cycloalkyl, and 3- 8 membered saturated ring optionally having one or two N atom which ring optionally substituted by hydroxy or alkanoyl,

or 3-8 membered saturated or unsaturated ring optionally having one or two hetero atoms selected from the group consisting of N and O, and which ring is optionally substituted by one or two substituents selected from the group consisting of alkyl, halogen, alkoxy, nitro, amino, cyano, alkylamino, di(alkyl)amino, 4-7 membered saturated cyclic amine optionally substituted by hydroxy, and mono-, di-, or tri-halogen substituted alkyl;

R^2 represents $-COR^{21}$, $-(CH_2)_n-R^{21}$ or tert-butyl,

Wherein R^{21} is alkoxy, hydroxy, mono-, di-, or tri- halogen substituted alkyl,

or 3-8 membered saturated or unsaturated ring optionally having one or two heteroatoms selected from the group consisting of N, O, and S and which ring is optionally substituted by one or two substituents independently selected from the group consisting of alkanoyl, halogen, benzyl, alkoxycarbonyl, haloalkyloxy-carbonyl, cyano, hydroxy, amino, alkylamino, di(alkyl)amino, cycloalkylamino, alkoxy-carbonyl, sulfamoyl, alkylaminosulfonyl, di(alkyl)aminosulfonyl, alkanoyl, alkanoylamino, carbamoyl, alkylcarbamoyl, di-(alkyl)carbamoyl, alkylsulfonyl,

alkyl optionally substituted by alkoxycarbonyl or mono-, di-, or tri-halogen, alkoxy optionally substituted by mono-, di-, or tri- halogen, and alkylthio optionally substituted by mono-, di-, or tri- halogen;

n is 0 or 1;

5 R³ and R⁴ independently represent hydrogen, halogen, cyano, hydroxy, amino, alkylamino, di(alkyl)amino, cycloalkylamino, carboxy, alkoxycarbonyl, sulfamoyl, alkyl-aminosulfonyl, di(alkyl)aminosulfonyl, alkanoyl, alkanoylamino, carbamoyl, alkylcarbamoyl, di-(alkyl)carbamoyl, alkylsulfonyl, alkyl optionally substituted by hydroxy, alkoxycarbonyl or mono-, di-, or tri-halogen, alkoxy optionally substituted by mono-, di-, or tri- halogen, or alkylthio optionally substituted by mono-, di-, or tri- halogen;

R⁵ represents hydrogen, hydroxy, nitro, cyano, halogen, sulfamoyl, alkylsulfonyl, alkylaminosulfonyl, di(alkyl)aminosulfonyl, $-(CH_2)_m-CO-R^{50}$, $-(CH_2)_m-R^{51}$, $-NR^{52}R^{53}$, or $-OR^{54}$,

15 wherein m is 0, 1, 2, or 3

R⁵⁰ is hydroxy, hydrogen, alkoxy, morpholino, di(phenyl)methyloxy, di(halogen substituted phenyl)methyloxy, $-NR^{501}R^{502}$ (wherein said R⁵⁰¹ and R⁵⁰² independently represent hydrogen, alkoxyalkyl, alkyl, hydroxyalkyl, alkoxycarbonylalkyl, or carboxyalkyl or

20 R⁵⁰¹ and R⁵⁰² together form with the adjuscent N atom, morpholino, piperazino optionally substituted by oxo, or 4-7 membered saturated cyclic amino optionally substituted by one substituent selected from the group consisting of carboxy, hydroxyalkyl, hydroxy, and carbamoyl) or alkyl optionally substituted by halogen,

25 R⁵¹ is hydrogen, hydroxy, or $-NR^{511}R^{512}$ (wherein said R⁵¹¹ and R⁵¹² independently represent hydrogen, alkoxyalkyl, alkyl, hydroxyalkyl, alkoxycarbonylalkyl, or carboxyalkyl, or R⁵¹¹ and R⁵¹² together form with the adjuscent N atom, 4-7 membered saturated cyclic amino optionally substituted by one substituent selected from the group consisting of carboxy, hydroxyalkyl, hydroxy, and carbamoyl),

30

R^{52} and R^{53} independently represent hydrogen, alkyl, hydroxy, cycloalkylcarbonyl, hydroxyalkyl, alkylsulfonyl, hydroxyalkylcarbonyl, carboxyalkylcarbonyl, alkanoyloxyalkylcarbonyl, or alkoxycarbonylalkylcarbonyl, or R^{52} and R^{53} together form with adjacent N atom, morpholino, cyclic amino optionally substituted by one substituent selected from the group consisting of carboxy, hydroxyalkyl, hydroxy, and carbamoyl,

R^{54} represents alkyl optionally substituted by morpholino, amino, di(alkyl)amino, carboxy, alkoxycarbonyl, or mono-, di-, or tri- halogen, or piperazino substituted by carboxy;

R^6 and R^7 independently represents hydrogen, morpholino, hydroxypyrrolidinylcarbonyl, hydroxyalkylaminocarbonyl, cyano, hydroxy, hydroxyalkyl, hydroxyamino, carboxy, fluoro, chloro, bromo, nitro, amino, alkylamino, di(alkyl)amino, cycloalkylamino, alkoxycarbonyl, sulfamoyl, alkylaminosulfonyl, di(alkyl)aminosulfonyl, alkanoyl, alkanoylamino, carbamoyl, diphenylmethyloxycarbonyl, alkylcarbamoyl, di-(alkyl)carbamoyl, alkylsulfonyl, alkyl optionally substituted by alkoxyalkyl(alkyl)amino, di(alkyl)amino, alkoxycarbonyl, carboxy, or mono-, di-, or tri-halogen, alkoxy optionally substituted by morpholino, di(alkyl)amino, or mono-, di-, or tri- halogen, or C_{1-6} alkylthio optionally substituted by mono-, di-, or tri- halogen

or R^6 and R^7 together form phenyl fused to adjacent phenyl; and

X represents $CR^{10}R^{11}$, NR^{12} , S, O, SO_2 , or SO

wherein R^{10} , R^{11} , and R^{12} independently represent hydrogen or methyl.

2. The phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1:

wherein

X represents CH_2 , NH, S, O, SO_2 , or SO;

R^1 represents C_3 to C_8 cycloalkyl,

C_1 - C_6 alkyl optionally substituted by one or two substituents selected from the group consisting of C_1 - C_6 alkoxy, amino, C_1 - C_6 alkylamino, di(C_1 - C_6 alkyl)amino, C_1 - C_6

alkanoyloxy, hydroxy, C₃-C₈ cycloalkyl, carboxy, C₁-C₆ alkoxy, C₃-C₈ cycloalkylphenyloxy, halogen, morpholino, and pyrrolidinyl,

pyridyl, pyrrolidinyl, piperidinyl optionally substituted by methyl, or

phenyl optionally substituted by one selected from the group consisting of halogen, C₁-C₆ alkoxy, nitro, amino, cyano, C₁-C₆alkylamino, di(C₁-C₆alkyl)amino, and mono-, di- or tri- halogen substituted C₁-C₆alkyl,

R² represents -COR²¹ or -(CH₂)_n-R²¹, wherein R²¹ represents mono-, di-, tri- halogen substituted C₁-C₆ alkyl, morpholino, C₁-C₆ alkoxy, hydroxy, C₃ to C₈ cycloalkyl, pyridyl, furanyl, thiophenyl, pyrrolidinyl, piperidinyl optionally substituted by one substituent selected from the group consisting of benzyl, C₁-C₆ alkoxy, C₃ to C₈ cycloalkyl, and halo C₁-C₆ alkoxy, C₃ to C₈ cycloalkyl, or phenyl optionally substituted by one substituent selected from the group consisting of C₁-C₆ alkyl, halogen, C₁-C₆ alkoxy, and mono-, di-, or tri- halogen substituted C₁-C₆alkyl;

n is 0 or 1;

R³ and R⁴ independently represent hydrogen, halogen, cyano, hydroxy, amino, C₁-C₆ alkylamino, di(C₁-C₆ alkyl)amino, C₃-C₈ cycloalkylamino, C₁-C₆ alkoxy, C₃ to C₈ cycloalkyl, C₁-C₆ alkylaminosulfonyl, di(C₁-C₆ alkyl)aminosulfonyl, C₁-C₆ alkanoyl, C₁-C₆ alkanoylamino, carbamoyl, C₁-C₆ alkylcarbamoyl, di-(C₁-C₆ alkyl)carbamoyl, C₁-C₆ alkylsulfonyl, C₁-C₆ alkyl optionally substituted by C₁-C₆ alkoxy, C₃ to C₈ cycloalkyl, or mono-, di-, or tri-halogen, C₁-C₆ alkoxy optionally substituted by mono-, di-, or tri- halogen, or C₁-C₆ alkylthio optionally substituted by mono-, di-, or tri- halogen;

R⁵ represents hydrogen, nitro, cyano, hydroxy, halogen, sulfamoyl, C₁-C₆alkylsulfonyl, C₁-C₆alkylaminosulfonyl, di(C₁-C₆alkyl)aminosulfonyl, -(CH₂)_m-CO-R⁵⁰, -(CH₂)_m-R⁵¹, -NR⁵²R⁵³, or -OR⁵⁴,

wherein

m is 0, 1, 2, or 3

R⁵⁰ is hydroxy, hydrogen, C₁-C₆alkoxy, morpholino, diphenylmethoxy, -NR⁵⁰¹R⁵⁰² (wherein said R⁵⁰¹ and R⁵⁰² independently represent hydrogen, C₁-C₆alkoxyalkyl, C₁-C₆alkyl, hydroxy C₁-C₆alkyl, C₁-C₆alkoxy, C₃ to C₈ cycloalkyl, C₁-C₆alkoxy, C₃ to C₈ cycloalkyl, or carboxy C₁-C₆alkyl or R⁵⁰¹ and R⁵⁰² together form with the adjacent N atom morpholino, 4-6 membered saturated cyclic amino

optionally substituted by one substituent selected from the group consisting of carboxy, hydroxyalkyl, hydroxy, and carbamoyl) or C₁-C₆ alkyl optionally substituted by halogen,

5 R⁵¹ is hydrogen, hydroxy, or -NR⁵¹¹R⁵¹² (wherein said R⁵¹¹ and R⁵¹² independently represent hydrogen, C₁-C₆ alkoxyalkyl, C₁-C₆ alkyl, hydroxyalkyl, C₁-C₆ alkoxycarbonylalkyl, or carboxyalkyl or R⁵¹¹ and R⁵¹² together form with the adjacent N atom, 4-7 membered saturated cyclic amino optionally substituted by one substituent selected from the group consisting of carboxy, hydroxyalkyl, hydroxy, and carbamoyl)

10 R⁵² and R⁵³ independently represent hydrogen, C₁-C₆ alkyl, hydroxy, C₃-C₈cycloalkylcarbonyl, or hydroxy C₁-C₆ alkyl or R⁵² and R⁵³ together form with adjacent N atom, morpholino, 4-7 membered saturated cyclic amino optionally substituted by one substituent selected from the group consisting of carboxy, hydroxyalkyl, hydroxy, and carbamoyl

15 R⁵⁴ represents alkyl optionally substituted by morpholino, amino, or di(alkyl) amino, or mono-, di-, or tri- halogen; and

20 R⁶ and R⁷ independently represent hydrogen, morpholino, hydroxypyrrolidinylcarbonyl, hydroxyC₁-C₆alkylaminocarbonyl, cyano, hydroxy, hydroxyC₁-C₆alkyl, hydroxyamino, carboxy, fluoro, chloro, bromo, nitro, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxycarbonyl, sulfamoyl, C₁₋₆ alkylaminosulfonyl, di(C₁₋₆ alkyl)aminosulfonyl, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, diphenylmethyloxycarbonyl, C₁₋₆ alkylcarbamoyl, di-(C₁₋₆ alkyl)carbamoyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkyl optionally substituted by alkoxyalkyl(alkyl)amino, di(alkyl)amino, C₁₋₆ alkoxy carbonyl, carboxy, or mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by morpholino, di(alkyl)amino, or mono-, di-, or tri-halogen, or C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri-halogen

or R⁶ and R⁷ together form phenyl fused to adjacent phenyl.

30 3. The phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

X represents CH_2 , NH, S, or SO;

R¹ represents cyclopropyl, pyridyl,

phenyl optionally substituted by halogen, C₁-C₆alkoxy, nitro, amino, cyano, C₁-C₆alkylamino, di(C₁-C₆alkyl)amino, or halogen substituted C₁-C₆alkyl,

5 C₁-C₆ alkyl optionally substituted by one or two substituents selected from the group consisting of C₁-C₆alkoxy, amino, C₁-C₆ alkylamino, di(C₁-C₆ alkyl)amino, C₁-C₆ alkanoyloxy, hydroxy, C₃-C₈ cycloalkyl, carboxy, C₁-C₆ alkoxycarbonyl, C₃-C₈ cycloalkylphenyloxy, halogen, morpholino, and pyrrolidinyl,

pyrrolidinyl, or piperidinyl optionally substituted by methyl;

10 R² represents $-\text{COR}^{21}$ or $-(\text{CH}_2)_n-\text{R}^{21}$, wherein R²¹ represents mono-, di- or tri-halogen substituted alkyl, morpholino, C₁-C₆alkoxy, hydroxy, C₃ to C₈ cycloalkyl, pyridyl, furanyl, thiophenyl, pyrrolidinyl, piperidinyl optionally substituted by one selected from the group consisting from benzyl, C₁-C₆alkoxycarbonyl, and haloC₁-C₆alkyloxycarbonyl, or phenyl optionally substituted by one selected from
15 the group consisting of C₁-C₆ alkyl, halogen, C₁-C₆ alkoxy, and mono-, di- or tri-halogen substituted C₁-C₆alkyl;

n is 0 or 1;

R³ and R⁴ independently represent hydrogen, halogen, methyl, or amino;

20 R⁵ represents hydrogen, morpholino, hydroxypyrrolidinylcarbonyl, hydroxyalkylamino-carbonyl, cyano, hydroxy, hydroxyalkyl, hydroxyamino, carboxy, fluoro, chloro, bromo, nitro, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxycarbonyl, sulfamoyl, C₁₋₆ alkylaminosulfonyl, di(C₁₋₆ alkyl)aminosulfonyl, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, diphenylmethyloxycarbonyl, C₁₋₆ alkylcarbamoyl, di-(C₁₋₆ alkyl)carbamoyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkyl optionally
25 substituted by alkoxyalkyl(alkyl)amino, di(alkyl)amino, C₁₋₆ alkoxycarbonyl, carboxy, or mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by morpholino, di(alkyl)amino, or substituted by mono-, di-, or tri- halogen, or C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen; and

R⁶ and R⁷ represent hydrogen,

30 or R⁶ and R⁷ together form phenyl fused to adjacent phenyl.

4. The phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

X represents CH_2 , NH , or S ;

- 5 R^1 represents cyclopropyl, pyridyl, phenyl optionally substituted by halogen, alkoxy, nitro, amino, cyano, alkylamino, di(alkyl)amino, or halogen substituted alkyl,

$\text{C}_1\text{-C}_6$ alkyl optionally substituted by one or two substituents selected from the group consisting of alkoxy, amino, $\text{C}_1\text{-C}_6$ alkylamino, di($\text{C}_1\text{-C}_6$ alkyl)amino, $\text{C}_1\text{-C}_6$ alkanoyloxy, hydroxy, $\text{C}_3\text{-C}_8$ cycloalkyl, carboxy, $\text{C}_1\text{-C}_6$ alkoxycarbonyl, $\text{C}_3\text{-C}_8$ cycloalkylphenoxy, halogen, morpholino, and pyrrolidinyl,

pyrrolidiny, or piperidinyl optionally substituted by methyl.

5. The phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

- 15 X represents CH_2 , NH , or S ;

R^2 represents $-\text{COR}^{21}$, $-(\text{CH}_2)_n\text{R}^{21}$, wherein R^{21} is phenyl optionally substituted by $\text{C}_1\text{-C}_6$ alkyl, halogen, halogen substituted alkyl or alkoxy and n is 0 or 1.

6. The phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

20 wherein

X represents CH_2 , NH , or S ;

R^3 and R^4 independently represent hydrogen, halogen, methyl, amino; and

- 25 R^5 represents hydrogen, morpholino, hydroxypyrrolidinylcarbonyl, hydroxyalkylaminocarbonyl, cyano, hydroxy, hydroxyalkyl, hydroxyamino, carboxy, fluoro, chloro, bromo, nitro, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{3-8} cycloalkylamino, C_{1-6} alkoxycarbonyl, sulfamoyl, C_{1-6} alkylaminosulfonyl, di(C_{1-6} alkyl)aminosulfonyl, C_{1-6} alkanoyl, C_{1-6} alkanoylamino, carbamoyl, diphenylmethyloxycarbonyl, C_{1-6} alkylcarbamoyl, di-(C_{1-6} alkyl)carbamoyl, C_{1-6} alkylsulfonyl,

C₁₋₆ alkyl optionally substituted by alkoxyalkyl(alkyl)amino, di(alkyl)amino, C₁₋₆ alkoxy carbonyl, carboxy, or mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by morpholino, di(alkyl)amino, or substituted by mono-, di-, or tri-halogen, or C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri-halogen; and

5 R⁶ and R⁷ represents hydrogen.

7. The phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein said phenyltriazole derivative of the formula (I) is selected from the group consisting of:

(4-{3-cyclopropyl-5-[(diphenylmethyl)thio]-4H-1,2,4-triazol-4-yl}phenyl)dimethylamine;

10 (4-{3-[(diphenylmethyl)thio]-5-ethyl-4H-1,2,4-triazol-4-yl}phenyl)dimethylamine;

(4-{3-[(diphenylmethyl)thio]-5-propyl-4H-1,2,4-triazol-4-yl}phenyl)dimethylamine;

[4-(3-cyclopropyl-5-{[(2-methylphenyl)(phenyl)methyl]thio}-4H-1,2,4-triazol-4-yl)phenyl]dimethylamine;

15 [4-(3-{[bis(4-chlorophenyl)methyl]thio}-5-cyclopropyl-4H-1,2,4-triazol-4-yl)phenyl]dimethylamine;

[4-(3-cyclopropyl-5-{[(4-methylphenyl)(phenyl)methyl]thio}-4H-1,2,4-triazol-4-yl)phenyl]dimethylamine;

[4-(3-{[bis(4-fluorophenyl)methyl]thio}-5-cyclopropyl-4H-1,2,4-triazol-4-yl)phenyl]dimethylamine;

20 [4-(3-{[(4-chlorophenyl)(phenyl)methyl]thio}-5-cyclopropyl-4H-1,2,4-triazol-4-yl)phenyl]dimethylamine;

(4-{3-cyclobutyl-5-[(diphenylmethyl)thio]-4H-1,2,4-triazol-4-yl}phenyl)dimethylamine;

(4-{3-butyl-5-[(diphenylmethyl)thio]-4H-1,2,4-triazol-4-yl}phenyl)dimethylamine;

25 [4-(3-{[bis(4-methylphenyl)methyl]thio}-5-cyclopropyl-4H-1,2,4-triazol-4-yl)phenyl]dimethylamine;

{4-[3-cyclopropyl-5-({phenyl[4-(trifluoromethyl)phenyl]methyl} thio)-4H-1,2,4-triazol-4-yl]phenyl} dimethylamine;

[4-(3-{{[(4-chlorophenyl)(cyclohexyl)methyl]thio}-5-cyclopropyl-4H-1,2,4-triazol-4-yl}phenyl)]dimethylamine;

3-[(diphenylmethyl)thio]-5-ethyl-4-(4-isopropylphenyl)-4H-1,2,4-triazole;

5 {4-[3-{{[bis(4-chlorophenyl)methyl]thio}-5-(3-fluorophenyl)-4H-1,2,4-triazol-4-yl}phenyl]}dimethylamine;

[4-(3-{{[bis(4-chlorophenyl)methyl]thio}-5-propyl-4H-1,2,4-triazol-4-yl}phenyl)]dimethylamine;

3-(3-{{[bis(4-chlorophenyl)methyl]thio}-5-propyl-4H-1,2,4-triazol-4-yl})benzoic acid;

10 3-{5-{{[bis(4-chlorophenyl)methyl]thio}-4-[4-(dimethylamino)phenyl]-4H-1,2,4-triazol-3-yl}}propan-1-ol;

3-[3-{{[bis(4-chlorophenyl)methyl]thio}-5-(3-fluorophenyl)-4H-1,2,4-triazol-4-yl}]benzoic acid;

3-[3-{{[bis(4-chlorophenyl)methyl]thio}-5-(3-fluorophenyl)-4H-1,2,4-triazol-4-yl}]phenol;

3-(3-{{[bis(4-chlorophenyl)methyl]thio}-5-propyl-4H-1,2,3-triazol-4-yl})benzoic acid;

15 3-(3-{{[bis(4-chlorophenyl)methyl]thio}-5-cyclopropyl-4H-1,2,4-triazol-4-yl})benzoic acid;

5-[3-{{[bis(4-chlorophenyl)methyl]thio}-5-(3-fluorophenyl)-4H-1,2,4-triazol-4-yl]-2-(dimethyl-amino)benzoic acid;

1-[4-(3-{{[bis(4-chlorophenyl)methyl]thio}-5-propyl-4H-1,2,4-triazol-4-yl}phenyl)]-piperidine-3-carboxylic acid; and

20 1-{4-[3-{{[bis(4-chlorophenyl)methyl]thio}-5-(3-fluorophenyl)-4H-1,2,4-triazol-4-yl]}phenyl}-piperidine-3-carboxylic acid.

8. A medicament comprising a phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 in as an active ingredient.

25 9. The medicament as claimed in claim 8, further comprising one or more pharmaceutically acceptable excipients.

10. The medicament as claimed in claim 8, wherein said phenyltriazole derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a GABA_B agonist.
11. The medicament as claimed in claim 8 for the treatment and/or prevention of an urological disorder or disease.
12. The medicament as claimed in claim 11, wherein said urological disorder or disease is urge urinary incontinence, overactive bladder, benign prostatic hyperplasia.
13. The medicament as claimed in claim 11 for the treatment and/or prevention of pain.
14. The medicament as claimed in claim 11 for the treatment and/or prevention of spasticity and motor control disorders, epilepsy, cognitive defects, psychiatric disorders, alcohol dependence and withdrawal, feeding behaviour, cardiovascular, respiratory disorders, or gastrointestinal disorders.
15. Use of a compound according to claim 1 for manufacturing a medicament for the treatment and/or prevention of an urological disorder or disease.
16. Use of a compound according to claim 1 for manufacturing a medicament for the treatment and/or prevention of pain.
17. Process for controlling an urological disorder or disease in humans and animals by administration of an GABA_B-agonistically effective amount of a compound according to claim 1.
18. Process for controlling pain in humans and animals by administration of a GABA_B-agonistically effective amount of a compound according to claim 1.